Organovo Holdings Company Profile (AMEX:ONVO)

About Organovo Holdings (AMEX:ONVO)

Organovo Holdings logoOrganovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: AMEX:ONVO
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $2.08
  • 200 Day Moving Avg: $2.61
  • 52 Week Range: $1.75 - $4.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.33 million
  • Price / Sales: N/A
  • Book Value: $0.54 per share
  • Price / Book: 3.65
  • EBIDTA: ($38,770,000.00)
  • Net Margins: -1,020.40%
  • Return on Equity: -67.74%
  • Return on Assets: -61.91%
  • Average Volume: 807,516 shs.
  • Short Ratio: 21.68

Frequently Asked Questions for Organovo Holdings (AMEX:ONVO)

What is Organovo Holdings' stock symbol?

Organovo Holdings trades on the AMEX under the ticker symbol "ONVO."

Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?

2 analysts have issued twelve-month target prices for Organovo Holdings' shares. Their predictions range from $3.75 to $3.75. On average, they expect Organovo Holdings' share price to reach $3.75 in the next year. View Analyst Ratings for Organovo Holdings.

Who are some of Organovo Holdings' key competitors?

Who are Organovo Holdings' key executives?

Organovo Holdings' management team includes the folowing people:

  • Taylor J. Crouch, President, Chief Executive Officer
  • Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
  • Sharon Collins Presnell Ph.D., Chief Scientific Officer
  • Jennifer Kinsbruner Bush J.D., Compliance Officer, General Counsel, Corporate Secretary
  • Paul Gallant, General Manager
  • Richard Maroun, Director
  • Robert F. Baltera Jr., Lead Independent Director
  • James T. Glover, Independent Director
  • Richard A. Heyman Ph.D., Independent Director
  • Tamar D. Howson, Independent Director

How do I buy Organovo Holdings stock?

Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo Holdings' stock price today?

One share of Organovo Holdings stock can currently be purchased for approximately $1.97.

MarketBeat Community Rating for Organovo Holdings (AMEX ONVO)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about Organovo Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Organovo Holdings (AMEX:ONVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.75

Analysts' Ratings History for Organovo Holdings (AMEX:ONVO)
DateFirmActionRatingPrice TargetDetails
6/12/2017Evercore ISILower Price TargetOutperform$4.00 -> $3.75View Rating Details
1/25/2017Raymond James Financial, Inc.Initiated CoverageOutperformView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Organovo Holdings (AMEX:ONVO)
No earnings announcements for this company have been tracked by


Earnings Estimates for Organovo Holdings (AMEX:ONVO)
Current Year EPS Consensus Estimate: $-0.39 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS


Dividend History for Organovo Holdings (AMEX:ONVO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Organovo Holdings (AMEX:ONVO)
No insider trades for this company have been tracked by


Headline Trends for Organovo Holdings (AMEX:ONVO)
Latest Headlines for Organovo Holdings (AMEX:ONVO)
DateHeadline logoHere's Why Organovo Holdings Inc Fell 10.5% in June - July 10 at 11:29 AM logoOrganovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q4, 2017 By the Numbers : June 13, 2017 - June 13 at 10:37 AM logoEvercore ISI Lowers Organovo Holdings Inc (ONVO) Price Target to $3.75 - June 12 at 3:38 PM logoOrganovo Announces Fiscal Fourth-Quarter and Full-Year 2017 Results; Company Issues Full-Year Fiscal 2018 Outlook - June 7 at 6:52 PM logoOrganovo reports 4Q loss - June 7 at 6:52 PM logo3 Stocks That Could Put's Returns to Shame - May 24 at 10:14 AM logoEQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc. - ITCI - May 13 at 12:47 AM logoOrganovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 2, 2017 - May 2 at 11:11 AM logoOrganovo Collaborates With University of Virginia to Develop Bioprinted Tissues for Volumetric Muscle Loss Injury - May 1 at 12:04 PM logoOrganovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 24 at 5:51 PM logoWhy Organovo Holdings Inc Shareholders Have Something to Worry About - April 18 at 5:48 PM logoBRIEF-Organovo reports CEO transition - April 11 at 6:55 PM logoWhat's Next for Organovo Holdings Inc.? - April 11 at 10:43 AM logoWhat's Next for Organovo Holdings Inc.? - April 11 at 7:30 AM logoOrganovo (ONVO) Publishes Data Describing Physiology of 3D Bioprinted Human Kidney Tissues for Drug Toxicity Testing - February 21 at 5:50 PM logoOrganovo Holdings' Unpleasant Q3 Surprise: Still Plenty of Skepticism About 3D Tissues - February 10 at 1:10 AM logoOrganovo Holdings Inc Earnings Call (Q3 2017) - February 9 at 1:01 AM logoCoverage initiated on Organovo by Raymond James - January 25 at 5:25 PM logoThe Possible Reason Behind Organovo Holdings, Inc.'s Big Climb in April - May 5 at 10:38 AM logo3 Ways Technology Is Set to Change the Face of Healthcare - March 19 at 9:04 AM logoOrganovo (ONVO) Announces Presentations of exVive3DTM Human Liver Model Data at SOT Annual Meeting - March 10 at 11:49 AM logoOrganovo and Its Customers Present Data Supporting 3D Bioprinted Liver Tissues for Drug Toxicity Testing and Liver Fibrosis Modeling - March 10 at 8:05 AM logo5 Key Takeaways from Organovo Holdings Inc.'s Investor Conference - February 12 at 2:42 PM logoORGANOVO HOLDINGS, INC. Financials - February 12 at 1:04 PM logoOrganovo Announces Fiscal Third-Quarter Results; Company Updates Full-Year Fiscal 2016 Outlook and Affirms Long-Range Guidance - February 8 at 4:10 PM logoORGANOVO HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report - February 8 at 4:09 PM logoWhat's Going on With Organovo Holdings, Inc.? - January 22 at 8:40 AM logoORGANOVO HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib - January 19 at 8:06 AM logo8:06 am Organovo: CFO Barry Michaels to retire at end of fiscal year - January 19 at 8:06 AM


Social activity is not available for this stock.
This page was last updated on 9/24/2017 by Staff